Abstract:BACKGROUND:Hepatitis B virus (HBV) recurrence may result in hepatic insufficiency or dysfunction of liver grafts. This study was to reevaluate the preventive effect of lamivudine therapy pretransplant on HBV recurrence after liver transplantation with combined lamivudine and hepatitis B immunoglobulin (HBIG) as a prophylactic regimen. METHODS:This is a single-center, retrospective study of 122 liver transplant recipients operated on from January 2002 to September 2006 at our hospital. All subjects showed positive hepatitis B surface antigen (HBsAg) and HBV DNA in blood, without HBV mutation in YMDD at the time of liver transplantation. The protocol with combined lamivudine and HBIG for preventing HBV recurrence was used on the day of operation. The initial immunosuppression therapy was identical. After one year follow-up, the recipients were divided into 2 groups: patients without HBV recurrence (group I) and patients with HBV recurrence (group II). Preoperative lamivudine therapy and postoperative mycophenolate mofetil (MMF) and glucocorticoid therapy were analyzed using the Wilcoxon's test and Stepwise logistic regression method. RESULTS:In the HBV recurrence group, the duration of pre-transplant lamivudine administration was significantly longer than that in the without HBV recurrence group (Z=-4.424, P=0.000). The HBV recurrence rate was significantly higher in patients with preoperative lamivudine therapy than in patients without lamivudine therapy (X2=13.11, P=0.000); the risk of HBV recurrence increased by a 10.909-fold in patients with pre-transplant lamivudine therapy compared with that in patients without lamivudine therapy (OR=10.909; 95% CI for OR: 2.86-41.67). Seven (63.6%) of 11 HBV recurrence recipients had YMDD mutants. The duration of MMF or glucocorticoid was not different between the 2 groups (Z(MMF)=-1.453, P(MMF)=0.146; Z(Pre)=-0.795, P(Pre)=0.427). No significant difference was noted in the HBV recurrent rate in patients with MMF duration < or =6 and >6 months (X2=0.185, P=0.667), as it was in patients with prednisone therapy < or =3 and >3 months (X2=0.067, P=0.793). CONCLUSIONS:With the protocol of combined lamivudine and HBIG for preventing HBV recurrence in liver transplantation recipients, liver transplantation candidates with positive HBV DNA should not be subjected to preoperative administration of lamivudine. A high dose of HBIG during the ahepatic period and in the early stage of post-transplantation can fulfill the treatment target as a long-term lamivudine therapy before liver transplantation. Long-term preoperative lamivudine treatment may result in an earlier HBV mutation in YMDD and increase the HBV recurrence rate and risk in the first year after transplantation.

Lamivudine in preventing liver damages and HBV reactivation in anti-HBc positive lymphoma patients during chemotherapy

Correlation of the Occurrence of YMDD Mutations with HBV Genotypes, HBV-DNA Levels, and HBeAg Status in Chinese Patients with Chronic Hepatitis B During Lamivudine Treatment

Lamivudine for the Prevention of Hepatitis B Virus Reactivation after High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Patients with Advanced or Relapsed Non-Hodgkin's Lymphoma Single Institution Experience

The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy

Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma

Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during Chemotherapy

A Study on the Clinical and Pathological Efficacy of Lamivudine in the Treatment of Chronic Hepatitis B

Detecting of the Hepatic Fibrotic Indexes and Serous Markers from Patients with Chronic Hepatitis B (chb)and Variation of HBV DNA YMDD

Comparison of Entecavir and Lamivudine in Preventing Hepatitis B Reactivation in Lymphoma Patients During Chemotherapy

Lamivudine for Prophylaxis Against Hepatitis B Virus Reinfection Following Orthotopic Liver Transplantation:An Clinical Analysis

Efficacy of adefovir dipivoxil in treatment of chronic hepatitis B patients with lamivudine resistance

Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis.

Efficacy of Combined Therapy in Patients with Hepatitis B Virus-Related Decompensated Cirrhosis.

Reevaluation of the Effect of Lamivudine Therapy Preoperative to Prevent Hbv Recurrence after Liver Transplantation

Effect of Telbivudine Therapy on the Cellular Immune Response in Chronic Hepatitis B

Antiviral therapy using lamivudine and thymosin alpha1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection

[Lamivudine As Prophylaxis Against Hepatitis B Virus Reinfection Following Orthotopic Liver Transplantation].

Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C

Role of Lamivudine with Transarterial Chemoembolization in the Survival of Patients with Hepatocellular Carcinoma

Hepatitis B Surface Antigen Seroconversion after HBV Reactivation in Non-Hodgkin’s Lymphoma

Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab